The Selzman Lab
The Selzman lab at the University of Utah is seeking to examine the role of inflammation in cardiac remodeling, as well as the transcriptional regulation and mechanisms of myocardial recovery, in models of pressure overload and ischemia-reperfusion injury. To investigate this, our team uses several in vitro and in vivo models, ranging from individual cardiomyocytes to transgenic mice, rats, as well as larger translational studies in swine and humans.
Research
The Selzman lab focuses on understanding the effect of novel therapies on different cardiovascular diseases and ischemia-reperfusion injury.
Transcriptional regulation in cardiac remodeling
- The lab studies transcription factors such as nuclear factor kappa B (NF-κB) and their role in mediating pathologic cardiac hypertrophy and heart failure.
- This work is important because identifying key regulatory pathways may lead to targeted therapies that reverse heart failure rather than only manage symptoms.
Metabolic and molecular mechanisms of myocardial recovery
- Research includes investigation of cardiac metabolism (e.g., pyruvate-lactate axis, glucose metabolism pathways) and how these pathways influence recovery after mechanical unloading (e.g., LVAD support).
- The lab integrates findings from human tissue, animal models, and cellular systems to identify therapeutic targets that promote recovery of the failing heart.
Utah Cardiac Recovery Group (UCAR)
- The Utah Cardiac Recovery Program (UCAR) is a multidisciplinary clinical and laboratory research. UCAR’s research priorities evolve in close coordination with its clinical programs, creating a continuous, bidirectional exchange in which scientific discovery informs patient care and clinical experience guides further investigation. This integrated approach strengthens both the program’s research capabilities and its clinical impact.
- Our lab is involved in research related to cardiac remodeling due to adverse molecular and structural myocardial changes, particularly in the setting of heart failure. Our goal is to determine established and novel therapies that can lead to ‘reverse remodeling’ to improve heart function
Effect of human amniotic fluid in models of myocardial infarction and ischemia-reperfusion injury
- Our lab has investigated the anti-inflammatory and immunomodulatory effects of human amniotic fluid in cardiovascular diseases, and others have shown promising results treating burns and chronic inflammatory diseases. We have shown that human amniotic fluid is a promising therapeutic option for cardiovascular disease demonstrated by preserved heart function and myocardial structure in models of ischemic heart failure and ischemia-reperfusion injury.
PRINCIPAL INVESTIGATOR
Craig H. Selzman, MD, is an established surgeon-scientist whose research focuses on understanding the mechanisms of heart failure and developing new strategies to restore cardiac function. As an Investigator at the Nora Eccles Harrison Cardiovascular Research and Training Institute (CVRTI) at the University of Utah, he leads clinical, basic science, and translational research.
His research interests include:
- Advanced heart failure and heart transplantation
- Ventricular assist devices and mechanical circulatory support
- Myocardial recovery and reverse cardiac remodeling
- Cardiac metabolism and molecular mechanisms of heart failure
- Ischemia-reperfusion injury
- Inflammation and transcriptional regulation in cardiovascular disease
- Novel therapies to promote cardiac recovery
- Clinical trials in heart support and transplantation technologies
Dr. Selzman leads an NIH-funded translational research laboratory that uses laboratory investigations, animal models, and human cardiac tissue to study the cellular, molecular, and metabolic processes involved in heart failure and recovery.
A central focus of his research is understanding why some patients with advanced heart failure regain cardiac function following mechanical circulatory support, including LVAD therapy. By identifying the biological mechanisms behind myocardial recovery, his team aims to develop treatments that could help more patients recover heart function. This work has contributed to the development of the Utah Cardiac Recovery Program.
Dr. Selzman also participates in clinical research evaluating next-generation cardiac support and transplantation technologies, including the BrioVAD system, HeartMate 3 ventricular assist devices, and advances in donor heart preservation. His research also examines ischemia-reperfusion injury and potential therapies to reduce cardiac damage and improve recovery.
Through an extensive body of peer-reviewed research, Dr. Selzman continues to advance our understanding of heart failure, mechanical circulatory support, and the potential for recovery in patients with advanced heart disease.
Team
Working with Craig Selzman, MD, is a multidisciplinary team of scientists, trainees, and collaborators within the Nora Eccles Harrison Cardiovascular Research and Training Institute (CVRTI) and the Utah Cardiac Recovery Program.
Working with Craig Selzman, MD, are scientists:
- Grace Mitchell, MD, PhD – Research Assistant Professor
- Douglas Smego, MD – Professor
- Carla Valenzuela Ripoll, MD – Postdoctoral Research Associate
- Jan Pierce, MBA – Cell Therapy & Regenerative Medicine Senior Director
Collaborative investigators and trainees
- The lab works closely with cardiovascular researchers, surgeons, and physician-scientists studying cardiac metabolism, remodeling, and recovery.
- Team members contribute to experimental design, animal models, molecular biology studies, and translational clinical research.
Highlighted Publications
- Determining the Individualized Probability of Myocardial Recovery: The Multicenter RecoverHeart Calculator
Taleb I, Kyriakopoulos C, Wever-Pinzon O, Maneta E, Selzman C, et al. J Heart Lung Transplant. 2026 online, article in press. DOI: 10.1016/j.healun.2026.04.008. The Utah Cardiac Recovery and Utah Transplant Affiliated Hospitals in collaboration with hospitals around the nation and other parts of the world. - Acellular human amniotic fluid protects the ischemic-reperfused rat myocardium
Young Sook Lee, Hadi Javan, Jo-Anna Reems, Ling Li, Jessica Lusty, Christine I. Schaaf, Jan Pierce, John D. Phillips, and Craig H. Selzman. Am J Physiol Heart Circ Physiol. 2022 322:3, H406-H416. https://doi.org/10.1152/ajpheart.00331.2021
Rather than targeting a single pathway implicated in myocardial reperfusion injury, cell-free human amniotic fluid—a naturally derived cocktail composed of thousands of proteins involved with innate immunity and anti-inflammation—markedly reduces injury and preserves cardiac function in a model of rodent myocardial ischemia-reperfusion. With its ubiquitous availability as well as its anti-inflammatory and nonimmunogenic properties, human cell-free amniotic fluid offers potential for use as a cardioprotective adjunct. - Proteomic Characterization of Cardioprotective Human Acellular Amniotic Fluid
Ryan Bia, Grace Mitchell, Hadi Javan, Ian Nickel, Jan Pierce, Craig H. Selzman, and Sarah Franklin. ACS Omega 2025 10 (7), 6918-6926. DOI: 10.1021/acsomega.4c09451. This study represents the first mass-spectrometry-based characterization of full-term, acellular hAF, suggesting that hAF offers a wide array of immune-modulating proteins working together to provide robust cardioprotection and a valuable treatment for ischemia-reperfusion injury. - Intravenous acellular human amniotic fluid prevents ischemic cardiac remodeling
Mitchell, G., Javan, H., Nickel, I. et al. Intravenous acellular human amniotic fluid prevents ischemic cardiac remodeling. Sci Rep. 2025 15: 44725. https://doi.org/10.1038/s41598-025-28735-7 . In this study we demonstrated that a single intravenous dose of acellular hAF provides functional cardioprotection that is mechanistically associated with cellular tolerance to hypoxic insult likely afforded by the plethora of naturally produced cytokines, chemokines, and immune-modulating proteins present in hAF. The ubiquitous availability of acellular hAF offers promising potential for its use as a cardioprotective adjunct. - CPT1a Expression Is a Critical Cardioprotective Response to Pathological Stress That Enables Rescue by Gene Transfer. Carley AN, Maurya SK, Maurya CK, Wang Y, Webb A, Challa AA, Gromova T, Vondriska TM, Zhang Z, Zhu H, Heydemann A, Bedi KC Jr, Kyriakopoulos CP, Selzman CH, Drakos SG, Margulies KB, Lewandowski ED.Circ Res. 2026 Jan 16;138(2):e327403. doi: 10.1161/CIRCRESAHA.125.327403. Epub 2025 Dec 4.PMID: 41342119
- The Role of Sphingolipids in Myocardial Recovery Mediated by Mechanical Unloading and Circulatory Support.Hamouche R, Tatum SM, Dranow E, Maschek JA, Kyriakopoulos CP, Shankar TS, Visker JR, Ling J, Sideris K, Selzman CH, Kfoury AG, Stehlik J, Alharethi R, Fang JC, Hong T, Navankasattusas S, Rondina MT, Holland WL, Summers SA, Drakos SG, Tseliou E.JACC Basic Transl Sci. 2026 Jan;11(1):101435. doi: 10.1016/j.jacbts.2025.101435. Epub 2025 Dec 19.PMID: 41418457
- Targeting leukocytes, neutrophil extracellular traps and cytokines: A conceptual review to prevent primary graft dysfunction after lung transplantation. Kagawa H, Contreras N, Goodwin M, Frye L, Raman S, Cahill B, Hachem R, Morrell M, Selzman CH.Transplant Rev (Orlando). 2026 Apr;40(2):100989. doi: 10.1016/j.trre.2025.100989. Epub 2025 Dec 26.PMID: 41478084
Contact Us
LAB
Selzman Lab
Division of Cardiothoracic Surgery
Nora Eccles Harrison Cardiovascular Research & Training Institute (CVRTI)
University of Utah
Email: Craig.Selzman@hsc.utah.edu
Address: 95 S 2000 E, Salt Lake City, UT 84112
CLINICAL TRIALS
Email: margaret.carlson@hsc.utah.edu
Address: 30 N Mario Capecchi Dr 4N145, Salt Lake City, UT 84112